Endocrine Pathology

, Volume 17, Issue 4, pp 345–354

Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma

EPS Proceedings


Discerning malignancy in resected adrenocortical neoplasms can pose diagnostic difficulty. Macroscopic examination is the first important step toward diagnosis and should include accurate measurement of weight and dimension of the specimens and description of the cut surface of the tumors. It is also important to sample the specimens for histological diagnosis near foci of hemorrhage and/or necrosis. Histological scoring systems evaluating multiple parameters, especially the criteria of Weiss, have been shown to be reliable in differential diagnosis between adrenocortical adenoma and carcinoma. A tumor is defined as adrenocortical carcinoma when three or more of the following criteria are met; (1) high nuclear grade, (2) mitotic rate six or more per 50 high power fields, (3) atypical mitosis, (4) clear cells less than 25%, (5) a diffuse architecture pattern in more than one-third of the tumor, (6) confluent necrosis, (7) venous invasion, (8) sinusoidal invasion, and (9) capsular invasion. The criteria are relatively straightforward and considered the most effective standard for diagnosis of adrenocortical malignancy. However, great care should be taken in applying the criteria to histological evaluation of two relatively rare and peculiar adrenocortical tumors, adrenocortical oncocytoma and pediatric adrenocortical neoplasms. At this juncture, ancillary biological or molecular markers are of little practical value in terms of differential diagnosis between adrenocortical adenoma and carcinoma but tumors with MIB1 or Ki-67 labeling index more than 2.5 may be considered malignant. Prognostic markers of adrenocortical carcinoma have not been established other than complete respectability of the tumor. There are also no surrogate markers for predicting response to therapy with Mitotane, an adrenolytic agent. It sometimes is important for surgical pathologists to differentiate adrenocortical carcinoma from metastatic malignancies of other sites. An immunohistochemical evaluation of adrenal 4 binding protein (Ad4BP) or SF-1, a transcription factor of all steroidogenesis, can aid in this differential diagnosis because nuclear immunoreactivity for this transcription factor is relatively specific to steroid producing cells.

Key Words

Adrenal cortex carcinoma pathology histology immunohistochemistry diagnosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sasano N. Functional pathology of adrenocortical endocrine disorders. Trans Soc Pathol Jpn 64:31–54, 1975.Google Scholar
  2. 2.
    Sasano N, Sasano H. The adrenal cortex. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. Oxford: Blackwell, 1998, 546–584.Google Scholar
  3. 3.
    Gandour, MJ, Grizzle WE. A small adrenocortical carcinoma with aggressive behavior. An evaluation of criteria for malignancy. Arch Pathol Lab Med 110:1076–1079, 1986.PubMedGoogle Scholar
  4. 4.
    Hough AJ, Hollifield, JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortex tumors: a mathematical analysis of clinical and morphological data. Am J Clin Pathol 72:390–399, 1979.PubMedGoogle Scholar
  5. 5.
    Weiss LM. Comparable histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163–169, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206, 1989.PubMedCrossRefGoogle Scholar
  7. 7.
    Sasano H, Suzuki T, Sano T, et al. Adrenocortical oncocytoma–a true nonfunctioning adrenocortical tumor. Am J Surg Pathol 15:949–956, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 15:973–978, 2002.PubMedCrossRefGoogle Scholar
  9. 9.
    Wieneke JA, Thompson LDR, Heffess CS Adrenal cortical neoplasms in the pediatric population. A clinicopathological and immunophenotypic analysis of 83 patients, Am J Surg Pathol 77:867–881, 2003.CrossRefGoogle Scholar
  10. 10.
    Lack EE, Mulivihil JJ, Travis WD, et al. Adrenocortical neoplasms in the pediatric and adolescent age group. Clinicopathological study of 30 cases with emphasis on epidemiological and prognostic factors. Pathol Annu 27:1–53, 1992.PubMedGoogle Scholar
  11. 11.
    Mickalkiexicz EL, Sandrini R, Figueriredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical registry. J Clin Oncol 22:838–845, 2004.CrossRefGoogle Scholar
  12. 12.
    Stojadinovic, A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 15:941–950, 2002.CrossRefGoogle Scholar
  13. 13.
    Stratakis CA. Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab 14:404–410, 2003.PubMedCrossRefGoogle Scholar
  14. 14.
    Sidhu S, Gicquel C, Bambach CP, et al. Clinical and molecular aspects of adrenocortical tumorigenesis. ANZ J Surg 73:727–738, 2003.PubMedCrossRefGoogle Scholar
  15. 15.
    Iino K, Sasano H, Yabuki N, et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 10:901–907, 1997.PubMedGoogle Scholar
  16. 16.
    Nakazumi H, Sasano H, Iino K, Ohashi Y, Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 11:1165–1170, 1998.PubMedGoogle Scholar
  17. 17.
    Martins ACP, Cologna AJ, Tucci S, et al. Clinical features and immunoexpression of p53, MIB-1 and proliferating cell nuclear antigen in adrenal neoplasms. J Urol 173:2138–2142, 2005.PubMedCrossRefGoogle Scholar
  18. 18.
    Bernini GP, Moretti A, Viacava, P, et al. Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues. Br J Cancer 86:1561–1565, 2002.PubMedCrossRefGoogle Scholar
  19. 19.
    Wachenfeld C, Beuschlein, F, Zwermann O, et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol 145:335–341, 2001.PubMedCrossRefGoogle Scholar
  20. 20.
    Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 57:176–182, 2001.PubMedCrossRefGoogle Scholar
  21. 21.
    Krishnamurthy S, Ordonez NG, Shelton TO, et al. Fine-needle aspiration cytology of a case of oncotytic adrenocortical carcinoma. Diagn Cytopathol 22:299–303, 2000.PubMedCrossRefGoogle Scholar
  22. 22.
    Sasano H, Shizawa S, Nagura H. Adrenocortical cytopathology. Am J Clin Pathol 104:161–166, 1995.PubMedGoogle Scholar
  23. 23.
    Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169:5–11, 2003.PubMedCrossRefGoogle Scholar
  24. 24.
    Harrison LF, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134:181–185, 1999.PubMedCrossRefGoogle Scholar
  25. 25.
    Hahner S, Fassnacht M. Mitotane for adreno-cortical carcinoma treatment. Curr Opin Investig Drugs 6:386–394, 2005.PubMedGoogle Scholar
  26. 26.
    Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in treatment of advanced adrenocortical carcinoma. Italian group study of adrenal cancer. Cancer 83:2194–2200, 1998.PubMedCrossRefGoogle Scholar
  27. 27.
    Neville AM, O'Hare MJ. The human adrenal cortex. Berlin, Germany: Springer Verlag, 1982.Google Scholar
  28. 28.
    Sasano H, Okamoto M, Sasano N. Immuno-histochemical study of human adrenal cortex with mineralo- and glucocorticoid excess. Virchows Arch [A] 413:313–318, 1988.Google Scholar
  29. 29.
    Sasano H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocrine J 41:471–482, 1994.Google Scholar
  30. 30.
    Sasano H. New approaches in human adrenocortical pathology: assessment of adrenocortical function in surgical specimen of human adrenal glands. Endocr Pathol 3:4–13, 1992.CrossRefGoogle Scholar
  31. 31.
    Tartour E, Caillou B, Tenenbaum F, et al. Immunohistochemical study of adrenocortical carcinoma: predictive value of the D11 monoclonal antibody. Cancer 72:3296–3303, 1993.PubMedCrossRefGoogle Scholar
  32. 32.
    Sasano H, Shizawa S, Suzuki T, et al. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol 26:1154–1156, 1995.PubMedCrossRefGoogle Scholar
  33. 33.
    Takayama K, Sasano H, Fukaya T, et al. Immunohistochemical localization of Ad4-binding protein with correlation to steroidogenic enzyme expression in cycling human ovaries and sex cord stromal tumors. J Clin Endocrinol Metab. 80:2815–2821, 1995.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2006

Authors and Affiliations

  • Hironobu Sasano
    • 1
  • Takashi Suzuki
    • 1
  • Takuya Moriya
    • 1
  1. 1.Department of PathologyTohoku University School of Medicine and Tohoku University HospitalSendaiJapan

Personalised recommendations